Claims
- 1. A method of treating a patient suffering from renal failure in combination with diabetes, obesity, hyperlipidemia or a combination thereof, wherein said method comprises introducing a peritoneal dialysis solution comprising N-acetylglucosamine (NAG) as an osmotic agent into the peritoneal cavity of the patient.
- 2. The method of claim 1 wherein the NAG is present at a concentration of about 0.5 to 5.0% (w/v).
- 3. The method of claim 2 wherein the peritoneal dialysis solution further comprises an additional osmotic agent selected from the group consisting of glucose, iduronic acid, glucuronic acid, and combinations therof.
- 4. A method of effecting peritoneal dialysis in a patient with renal failure in combination with diabetes, obesity, hyperlipidemia or a combination thereof, wherein said method comprises introducing a peritoneal dialysis solution comprising N-acetylglucosamine as an osmotic agent into the peritoneal cavity of the patient.
- 5. The method of claim 4, wherein the dialysis reduces or prevents hyperglycemia, hyperinsulinemia, hypertension or a combination thereof.
- 6. A method of reducing complications associated with peritoneal dialysis in a patient with diabetes, obesity, hyperlipidemia or a combination thereof, said method comprising introducing a peritoneal dialysis solution comprising N-acetylglucosamine as an osmotic agent into the peritoneal cavity of the patient.
- 7. The method of claim 6 wherein the NAG is present at a concentration of about 0.5 to 5.0% (w/v).
- 8. The method of claim 7 wherein the peritoneal dialysis solution further comprises at least one additional osmotic agent selected from the group consisting of glucose, iduronic acid, glucuronic acid, and a combination thereof.
- 9. The method of claim 6 wherein the complications asociated with peritoneal dialysis consist of:
(a) morphological and functional deterioration of the peritoneal membrane; (b) peritonitis; (c) adverse metabolic consequences and realted cardiovascular disease; (d) protein malnutrition; (e) hyperglycemia; (f) hyperinsulinemia; (g) hypertension; and combinations thereof.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims the benefit of U.S. Provisional Application No. 60/432,466, filed Dec. 10, 2002, which is hereby incorporated by reference to the extent not inconsistent with the disclosure herewith.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60432466 |
Dec 2002 |
US |